Showing 37 to 48 of 69 results
New Blood Test Shows Promise for Early Pancreatic Cancer Detection
Researchers in Zurich and Portland have developed a blood test that detects pancreatic cancer in early stages with 73% accuracy, offering hope against this deadly disease with a historically low survival rate due to late diagnosis.
New Blood Test Shows Promise for Early Pancreatic Cancer Detection
Researchers in Zurich and Portland have developed a blood test that detects pancreatic cancer in early stages with 73% accuracy, offering hope against this deadly disease with a historically low survival rate due to late diagnosis.
Progress
32% Bias Score
Sarah Harding-Inspired Study Identifies 88 Young Women at Increased Breast Cancer Risk
The BCAN-RAY study, inspired by Sarah Harding, has identified 88 young women at increased breast cancer risk, highlighting a critical need for earlier screening and intervention among younger women in the UK, currently lacking in national protocols that begin at age 50.
Sarah Harding-Inspired Study Identifies 88 Young Women at Increased Breast Cancer Risk
The BCAN-RAY study, inspired by Sarah Harding, has identified 88 young women at increased breast cancer risk, highlighting a critical need for earlier screening and intervention among younger women in the UK, currently lacking in national protocols that begin at age 50.
Progress
40% Bias Score
Brain Cancer Recurrence Prompts Clinical Trial
Professor Richard Scolyer, a 58-year-old Australian of the Year, faces potential recurrence of his aggressive brain cancer after a recent scan; surgery is scheduled for Monday to assess and potentially remove the tumor, though his prognosis remains 3-6 months, following an experimental treatment tha...
Brain Cancer Recurrence Prompts Clinical Trial
Professor Richard Scolyer, a 58-year-old Australian of the Year, faces potential recurrence of his aggressive brain cancer after a recent scan; surgery is scheduled for Monday to assess and potentially remove the tumor, though his prognosis remains 3-6 months, following an experimental treatment tha...
Progress
24% Bias Score
Cancer Cells Cooperate to Acquire Nutrients, Opening New Treatment Avenues
US and French scientists discovered that cancer cells cooperate to obtain nutrients by secreting an enzyme that breaks down oligopeptides into amino acids, creating a shared pool; blocking this enzyme with Bestatin or CRISPR significantly slows tumor growth, suggesting a novel treatment approach.
Cancer Cells Cooperate to Acquire Nutrients, Opening New Treatment Avenues
US and French scientists discovered that cancer cells cooperate to obtain nutrients by secreting an enzyme that breaks down oligopeptides into amino acids, creating a shared pool; blocking this enzyme with Bestatin or CRISPR significantly slows tumor growth, suggesting a novel treatment approach.
Progress
20% Bias Score
NCI Spends $218 Million on DEI Grants Amidst Push for Meritocracy
The National Cancer Institute (NCI) spends $218 million annually on grants promoting racial minority representation in its workforce, a practice criticized by the nonprofit Do No Harm amid broader efforts to curtail DEI spending within the federal government.
NCI Spends $218 Million on DEI Grants Amidst Push for Meritocracy
The National Cancer Institute (NCI) spends $218 million annually on grants promoting racial minority representation in its workforce, a practice criticized by the nonprofit Do No Harm amid broader efforts to curtail DEI spending within the federal government.
Progress
64% Bias Score
Spiky Tumor Structures Identified as Key Driver of Cancer Metastasis
Scientists discovered that aggressive breast and melanoma tumors have spiky structures that facilitate cancer spread, potentially leading to new treatments that prevent metastasis by targeting these spikes.
Spiky Tumor Structures Identified as Key Driver of Cancer Metastasis
Scientists discovered that aggressive breast and melanoma tumors have spiky structures that facilitate cancer spread, potentially leading to new treatments that prevent metastasis by targeting these spikes.
Progress
40% Bias Score
Yemaachi Biotech Builds Africa's First Comprehensive Cancer Database
Ghanaian immunologist Yaw Bediako's Yemaachi Biotech is creating Africa's first comprehensive cancer database, including data from 7,500 patients, to address the continent's high cancer mortality rate and improve treatment efficacy, supported by Roche.
Yemaachi Biotech Builds Africa's First Comprehensive Cancer Database
Ghanaian immunologist Yaw Bediako's Yemaachi Biotech is creating Africa's first comprehensive cancer database, including data from 7,500 patients, to address the continent's high cancer mortality rate and improve treatment efficacy, supported by Roche.
Progress
24% Bias Score
Brain Tumor Regrowth Leaves Former Australian of the Year with Months to Live
Former Australian of the Year Professor Richard Scolyer's aggressive brain tumor has regrown after multiple surgeries and experimental treatment, leaving him with a prognosis of months to live, despite exceeding typical survival rates by nine months; his case informs a world-first clinical trial for...
Brain Tumor Regrowth Leaves Former Australian of the Year with Months to Live
Former Australian of the Year Professor Richard Scolyer's aggressive brain tumor has regrown after multiple surgeries and experimental treatment, leaving him with a prognosis of months to live, despite exceeding typical survival rates by nine months; his case informs a world-first clinical trial for...
Progress
20% Bias Score
Stage Four Lung Cancer Diagnosis in a Never-Smoker Highlights Systemic Issues
A Stanford professor and primary care doctor, age 49, was diagnosed with stage four lung cancer, despite never smoking, highlighting the need for increased research funding and improved patient care for this deadly disease.
Stage Four Lung Cancer Diagnosis in a Never-Smoker Highlights Systemic Issues
A Stanford professor and primary care doctor, age 49, was diagnosed with stage four lung cancer, despite never smoking, highlighting the need for increased research funding and improved patient care for this deadly disease.
Progress
32% Bias Score
Blood Test Research for Early Diagnosis of Rare Womb Cancer
Researchers at the University of Leicester are developing a blood test to improve the diagnosis of uterine sarcomas, a rare womb cancer affecting 3% of womb cancer patients and often misdiagnosed as fibroids; this project, funded by The Eve Appeal and Sarcoma UK, aims to detect small fragments of tu...
Blood Test Research for Early Diagnosis of Rare Womb Cancer
Researchers at the University of Leicester are developing a blood test to improve the diagnosis of uterine sarcomas, a rare womb cancer affecting 3% of womb cancer patients and often misdiagnosed as fibroids; this project, funded by The Eve Appeal and Sarcoma UK, aims to detect small fragments of tu...
Progress
28% Bias Score
Fundraising Campaign for Rare Childhood Cancer Nears £100,000 Goal
The family of Liz Hatton, a 17-year-old photographer who died of desmoplastic small round cell tumor, is nearing its £100,000 fundraising goal to support research into the disease, holding a weekend event and planning a UK-wide support network.
Fundraising Campaign for Rare Childhood Cancer Nears £100,000 Goal
The family of Liz Hatton, a 17-year-old photographer who died of desmoplastic small round cell tumor, is nearing its £100,000 fundraising goal to support research into the disease, holding a weekend event and planning a UK-wide support network.
Progress
44% Bias Score
Brachyury Protein Discovery Opens New Avenues for Chordoma Treatment
An international team of researchers, led by Professor Paul Workman, has identified the protein brachyury as key to chordoma's survival, enabling the development of targeted drugs to potentially treat this rare cancer and potentially others.
Brachyury Protein Discovery Opens New Avenues for Chordoma Treatment
An international team of researchers, led by Professor Paul Workman, has identified the protein brachyury as key to chordoma's survival, enabling the development of targeted drugs to potentially treat this rare cancer and potentially others.
Progress
32% Bias Score
Showing 37 to 48 of 69 results